Alto Neuroscience to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in several upcoming investor conferences in September 2024. The company will host an Investor Day on September 9, focusing on ALTO-100 for Major Depressive Disorder, ahead of expected topline data in October 2024.

Alto will also present at the Baird Global Healthcare Conference (September 10-11), the Cantor Global Healthcare Conference (September 17-19), and the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (September 26). These events will feature presentations, one-on-one investor meetings, and a fireside chat, providing insights into Alto's progress and strategies.

– Alto to host investor day focused on ALTO-100 on September 9, 2024 –

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in September:

• Alto Investor Day Focused on ALTO-100 in Major Depressive Disorder, September 9^th 2024:
  • Ahead of topline data expected in October 2024 for the Phase 2b study, the Company plans to provide information regarding the baseline characteristics of study participants, mechanistic and clinical rationale for ALTO-100, and the predictive cognitive test being used to select patients.
  • To register for Alto’s investor day, being held on Monday, September 9, 2024, at 9:00 am ET, click here. More details are available on the Company’s investor day website.
• Baird Global Healthcare Conference, September 10-11^th 2024:
  • Format: Presentation and one-on-one investor meetings
  • Presentation Date/Time: Wednesday, September 11, 2024, at 11:25 am ET
  • Location: InterContinental New York Barclay
• Cantor Global Healthcare Conference, September 17-19^th 2024:
  • Format: Presentation and one-on-one investor meetings
  • Presentation Date/Time: Tuesday, September 17, 2024, at 9:10 am ET
  • Location: InterContinental New York Barclay
• TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit, September 26^th 2024:
  • Format: Fireside chat
  • Presentation Date/Time: Thursday, September 26, 2024, at 3:00 pm ET
  • Location: Virtual

Available presentations will be accessible via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.

For more information, visit www.altoneuroscience.com or follow Alto on X (Twitter).

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “expects,” “plans,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Alto’s expectations for the timing and results of Alto’s Phase 2b study of ALTO-100. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including uncertainties inherent in the initiation, progress and completion of clinical trials and other important factors, any of which could cause Alto’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section titled “Risk Factors” in Alto’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Alto may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alto expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as required by law.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website (https://investors.altoneuroscience.com) to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903163152/en/

Investor Contact:

Nick Smith

investors@altoneuroscience.com

Media Contact:

Mari Purpura

media@altoneuroscience.com

Source: Alto Neuroscience, Inc.

FAQ

When is Alto Neuroscience hosting its Investor Day focused on ALTO-100?

Alto Neuroscience is hosting its Investor Day focused on ALTO-100 on September 9, 2024, at 9:00 am ET.

What is the focus of Alto Neuroscience's Investor Day on September 9, 2024?

The Investor Day will focus on ALTO-100 for Major Depressive Disorder, providing information on study participant characteristics, mechanistic and clinical rationale, and the predictive cognitive test used for patient selection.

Which investor conferences will Alto Neuroscience (ANRO) participate in during September 2024?

Alto Neuroscience will participate in the Baird Global Healthcare Conference (September 10-11), Cantor Global Healthcare Conference (September 17-19), and TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit (September 26).

When is Alto Neuroscience (ANRO) expecting topline data for its Phase 2b study of ALTO-100?

Alto Neuroscience is expecting topline data for its Phase 2b study of ALTO-100 in October 2024.